A Multicenter, Randomized, Parallel-Group Trial Assessing Compliance, Tolerability, Safety, and Efficacy to Treatment with Grass Allergy Tablets in 261 Patients with Grass Pollen Rhinoconjunctivitis

Abstract EN

Background.

Allergen-specific sublingual immunotherapy (SLIT) is considered a causal treatment of respiratory allergies.

Compliance to the SLIT is an important aspect for a positive clinical outcome.

Study Aim.

To evaluate if compliance with grass Allergy Immunotherapy Tablet (AIT) can be increased by providing an electronic compliance device (CED) (Memozax; a tablet-container with a programmable daily acoustic alarm).

Patients and Methods.

261 patients with grass allergy were enrolled and randomized (1 : 1) to 1-year treatment with AIT (Grazax) using a CED (group A; n=122) or without (Group B, n=139).

Compliance was measured through tablet count at each visit.

Results.

The 12-month compliance, mean (SD), in group A was 83% (21) and 83% (24) in group B.

A total of 81% of patients reported a significant clinical improvement of symptoms after treatment in comparison with the previous year.

No severe adverse reactions were observed in the study.

Conclusion.

Compliance to the treatment with AIT administered for 12 consecutive months is in general good.

The use of CED is not associated with a greater compliance.

AIT treatment was associated with a significant clinical improvement in >80% of patients with a good tolerability and safety profile.